scholarly journals The advent of de novo proteins for cancer immunotherapy

2020 ◽  
Vol 56 ◽  
pp. 119-128 ◽  
Author(s):  
Alfredo Quijano-Rubio ◽  
Umut Y. Ulge ◽  
Carl D. Walkey ◽  
Daniel-Adriano Silva
Biochemistry ◽  
1999 ◽  
Vol 38 (29) ◽  
pp. 9495-9507 ◽  
Author(s):  
Cecilia Tommos ◽  
Jack J. Skalicky ◽  
Denis L. Pilloud ◽  
A. Joshua Wand ◽  
P. Leslie Dutton

2017 ◽  
Vol 2 (2) ◽  
pp. 158-169 ◽  
Author(s):  
Valerio Rizzo ◽  
Khalid Touzani ◽  
Bindu L. Raveendra ◽  
Supriya Swarnkar ◽  
Joan Lora ◽  
...  

2016 ◽  
Vol 21 (8) ◽  
pp. 769-785 ◽  
Author(s):  
Emma S. Hickman ◽  
Martine E. Lomax ◽  
Bent K. Jakobsen

Evidence of adaptive immune responses in the prevention of cancer has been accumulating for decades. Spontaneous T-cell responses occur in multiple indications, bringing the study of de novo expressed cancer antigens to the fore and highlighting their potential as targets for cancer immunotherapy. Circumventing the immune-suppressive mechanisms that maintain tumor tolerance and driving an antitumor cytotoxic T-cell response in cancer patients may eradicate the tumor or block disease progression. Multiple strategies are being pursued to harness the cytotoxic potential of T cells clinically. Highly promising results are now emerging. The focus of this review is the target discovery process for cancer immune therapeutics based on affinity-matured T-cell receptors (TCRs). Target cancer antigens in the context of adoptive cell transfer technologies and soluble biologic agents are discussed. To appreciate the impact of TCR-based technology and understand the TCR discovery process, it is necessary to understand key differences between TCR-based therapy and other immunotherapy approaches. The review first summarizes key advances in the cancer immunotherapy field and then discusses the opportunities that TCR technology provides. The nature and breadth of molecular targets that are tractable to this approach are discussed, together with the challenges associated with finding them.


Langmuir ◽  
2005 ◽  
Vol 21 (20) ◽  
pp. 9103-9109 ◽  
Author(s):  
Ying Hu ◽  
Aditi Das ◽  
Michael H. Hecht ◽  
Giacinto Scoles

ChemInform ◽  
2010 ◽  
Vol 32 (52) ◽  
pp. no-no
Author(s):  
David A. Moffet ◽  
Michael H. Hecht

1997 ◽  
Vol 2 (2) ◽  
pp. 89-92 ◽  
Author(s):  
Sushmita Roy ◽  
Kimberly J. Helmer ◽  
Michael H. Hecht

2006 ◽  
Vol 73 (4) ◽  
pp. 1320-1331 ◽  
Author(s):  
Alka Rao ◽  
Geeta Ram ◽  
Adesh Kumar Saini ◽  
Reena Vohra ◽  
Krishan Kumar ◽  
...  

ABSTRACT Recent advances in nonrational and part-rational approaches to de novo peptide/protein design have shown increasing potential for development of novel peptides and proteins of therapeutic use. We demonstrated earlier the usefulness of one such approach recently developed by us, called “codon shuffling,” in creating stand-alone de novo protein libraries from which bioactive proteins could be isolated. Here, we report the synthesis and selection of codon-shuffled de novo proteins that bind to a selected Mycobacterium tuberculosis protein target, the histone-like protein HupB, believed to be essential for mycobacterial growth. Using a versatile bacterial two-hybrid system that entailed utilization of HupB and various codon-shuffled protein libraries as bait and prey, respectively, we were able to identify proteins that bound strongly to HupB. The observed interaction was also confirmed using an in vitro assay. One of the protein binders was expressed in Mycobacterium smegmatis and was shown to appreciably affect growth in the exponential phase, a period wherein HupB is selectively expressed. Furthermore, the transcription profile of hupB gene showed a significant reduction in the transcript quantity in mycobacterial strains expressing the protein binder. Electron microscopy of the affected mycobacteria elaborated on the extent of cell damage and hinted towards a cell division malfunction. It is our belief that a closer inspection of the obtained de novo proteins may bring about the generation of small-molecule analogs, peptidomimetics, or indeed the proteins themselves as realistic leads for drug candidates. Furthermore, our strategy is adaptable for large-scale targeting of the essential protein pool of Mycobacterium tuberculosis and other pathogens.


Sign in / Sign up

Export Citation Format

Share Document